Your shopping cart is currently empty

Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid exhibiting anti-inflammatory and anti-cancer activities and can enhance the activation of p38 MAPK.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $53 | In Stock | In Stock | |
| 5 mg | $113 | In Stock | In Stock | |
| 10 mg | $163 | In Stock | In Stock | |
| 25 mg | $278 | In Stock | In Stock | |
| 50 mg | $417 | - | In Stock | |
| 100 mg | $593 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $126 | In Stock | In Stock |
| Description | Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid exhibiting anti-inflammatory and anti-cancer activities and can enhance the activation of p38 MAPK. |
| In vitro | Treatment of C2C12 myoblasts with 500 nM dehydrocorydrine increased the expression of muscle-specific proteins (including MyoD, myogenin, and myosin heavy chain), and enhanced p38 MAPK activation and the interaction between MyoD and E protein. Additionally, dehydrohydroxyproline restored defects in differentiation-induced p38 MAPK activation and differentiation of myoblasts caused by Cdo. Dehydrohydroxyproline significantly inhibited MCF-7 cell proliferation in a dose-dependent manner, reversible by the caspase-8 inhibitor Z-IETD-FMK. It also increased DNA fragmentation without affecting ΔΨm, elevated Bax protein levels, decreased Bcl-2 protein levels, and induced caspase-7 and -8 activation and PARP cleavage, without affecting caspase-9. These findings suggest that dehydrohydroxyproline inhibits MCF-7 cell proliferation by inducing apoptosis through Bax/Bcl-2 regulation, caspase activation, and PARP cleavage. |
| In vivo | Dehydrocobaltate (3.6, 6 or 10 mg/kg, intraperitoneal injection) showed a dose-dependent anti-nociceptive effect in the acetic acid-induced writhing test and significantly reduced formalin-induced mice Pain reaction. In the formalin test, dehydrocorydrine can reduce the expression of caspase 6 (CASP6), TNF-α, IL-1β and IL-6 proteins in the spinal cord. It was confirmed that dehydroyanhusine has an analgesic effect on mice. |
| Synonyms | 13-Methylpalmatine chloride |
| Molecular Weight | 401.88 |
| Formula | C22H24ClNO4 |
| Cas No. | 10605-03-5 |
| Smiles | [Cl-].COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC |
| Relative Density. | 1.23g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 24 mg/mL (59.72 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.98 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.